Harrow to acquire products from Santen, Novaliq
Click Here to Manage Email Alerts
Harrow announced that it signed agreements with Santen Pharmaceutical Co. affiliates to acquire their branded ophthalmic portfolio and also with Novaliq GmbH to acquire Vevye.
According to a press release from Harrow, the company will obtain certain commercial rights to Santen’s U.S. products Flarex (fluorometholone acetate ophthalmic suspension) 0.1%, Natacyn (natamycin ophthalmic suspension) 5%, Tobradex ST (tobramycin and dexamethasone ophthalmic suspension) 0.3%/0.05%, Verkazia (cyclosporine ophthalmic emulsion) 0.1%, Zerviate (cetirizine ophthalmic solution) 0.24% and Freshkote; and Canadian products Verkazia and Cationorm Plus.
Harrow Chairman and CEO Mark L. Baum said in the release: “We are excited to add several high-utility and trusted products that serve the ophthalmic surgical market, a market in which we already have a strong presence, and significantly expand the breadth of our portfolio, which will now include the only FDA-approved ophthalmic antifungal; a patented and ‘orphan-designated’ product for the nearly 50,000 Americans suffering from the rare disease vernal keratoconjunctivitis; a patented prescription drug to treat ocular itching associated with allergies; and two patented nonprescription brands serving patients managing dry eye symptoms.”
Harrow announced in a separate, joint press release with Novaliq that under the agreement, Harrow will acquire the U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%.
Baum commented on this transaction in the joint release: “We are particularly excited about adding Vevye to our portfolio because of our strong belief that the U.S. dry eye disease market is in need of a cyclosporine-based product that is generally well-tolerated, improves both the signs and symptoms of DED, and, critically, reduces the time it takes for patients to experience relief from this all-too-common and, in many cases, debilitating disease. ... We look forward to making Vevye available in the U.S. later this year.”
“Harrow and its commercial team have a distinguished track record for successfully commercializing new and clinically important pharmaceutical products in the U.S. market,” Novaliq CEO Christian Roesky, PhD, said in the release, “and they specifically have many years of experience successfully marketing cyclosporine-based formulations to U.S. eye care professionals. The Novaliq team looks forward to supporting Harrow during the launch of Vevye, a truly unique and powerful new treatment option for U.S. eye care professionals and the more than 16 million Americans who have been diagnosed with dry eye disease.”
Reference:
- Harrow acquires U.S. and Canadian commercial rights to Vevye (cyclosporine ophthalmic solution) 0.1% from Novaliq. https://investors.harrow.com/news-releases/news-release-details/harrow-acquires-us-and-canadian-commercial-rights-vevyer. Posted July 18, 2023. Accessed July 20, 2023.
Read more about
Click Here to Manage Email Alerts